Premier Alternatives

Validose

Brooklyn, NY · Founded 2017 · Privately Held (backing)

Developer of an intranasal drug delivery platform designed to deliver medication adherence solutions for clinical trials in real-time. Validose is based in Brooklyn, NY and was founded in 2017. It was valued at $6 million at its seed round in Jan 2025, the last priced event on record. It has raised $2 million across 1 recorded round; the latest was a $1.6 million seed round in Dec 2024.

PMV mark · valuation
$6.0M
Oct 2026
Priced at
its seed round
Jan 2025
Total raised
$2.0M
Last round
Seed Round
Dec 2024

Validose key facts

as of Oct 2026
  • Developer of an intranasal drug delivery platform designed to deliver medication adherence solutions for clinical trials in real-time.
  • Validose is valued at approximately $6.0M as of Oct 2026, set at its seed round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($1.6M) in Dec 2024.
  • Notable investors include Interstate Fusion Ventures, Bauer Family Office's Technology for Humanity, 10XBeta.
  • Validose has filed 1 Form D with the SEC, most recently Jan 2025 ($1.6M sold to 2 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$6.0M

Valued at $6.0M at its seed round, Jan 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Validose with a free account
  • ·Watch Validose: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Validose funding rounds

1 rounds
Dec 2024Seed Round$1.6MSEC filing▮
Full funding history →

Validose valuation

Validose was valued at $6 million at its seed round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Validose raised?

Validose has raised $2 million across 1 recorded round since 2024. The largest was a $1.6 million seed round in Dec 2024.

Validose has filed 1 Form D with the SEC, most recently in Jan 2025 ($1.6 million sold to 2 investors).

Validose investors

3 investors are on record for Validose, including Interstate Fusion Ventures, Bauer Family Office's Technology for Humanity and 10XBeta. By type, the record holds 3 venture capital firms. The seed round in Dec 2024 drew 2 investors.

About Validose

Developer of an intranasal drug delivery platform designed to deliver medication adherence solutions for clinical trials in real-time. The company's platform integrates with care management, clinical study, and population health platforms and also covers a range of delivery methods, and works with any medical formulation, enabling doctors to enhance patient care with insight for trial management and provide quality care to patients.

Sector
Healthcare
HQ
Brooklyn, NY, United States
Founded
2017
Employees
5
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.